Other headlines for [STJ]

• STJ Today 05:58am
  St Jude Medical Inc Price Target lowered to $42 from $52 at Merrill, maintains buy rating
  
• STJ Yesterday 05:05pm
  St Jude Medical Inc Guides Q4 EPS $0.56-0.66 v $0.61e, R $1.06-1.12B v $1.13Be- Guides FY 2009 EPS $2.47-2.52 (incl effect of foreign exchange) v $2.59e
  
• STJ 11/19/2008 07:24am
  St Jude Medical Inc Jefferies Initiates STJ with Hold, price target: $34
  
• STJ 11/17/2008 08:01am
  St Jude Medical Inc Japan approves Victory family of pacemakers, launches products in Japan- Victory pacemakers are engineered to accommodate a wide variety of the diagnostic and therapy needs of patients, including more...
  
• STJ 10/27/2008 08:30am
  St Jude Medical Inc Announces Publication of 20-Year Durability Data on Tissue Heart Valve- The Biocor valve was found to perform well on key measures of long-term performance including freedom from reoperation due to more...
  

Healthcare sector headlines

• CORT Today 09:00am
  Corcept Therapeutics Incorpora Names Caroline Loewy as new CFO- Ms. Loewy most recently served as CFO of Poniard Pharmaceuticals, a publicly traded biopharmaceutical company, where she was a key driver of that company's corporate more...
  
• LHCG Today 08:57am
  LHC Group Guides FY09 EPS $1.90-2.00 v $1.93e, R $450M-$470M v $436.2Me
  
• NPSP Today 08:50am
  NPS Pharmaceuticals Inc. Update: Initiates Phase 3 'STEPS' Study to Confirm GATTEX Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome- Patient enrollment has begun in a Phase 3 registrational study to confirm more...
  
• OCLS Today 08:48am
  Oculus Innovative Sciences Update: Signs development agreement with Bayer Taiwan for Microcyn tech in Taiwanese animal market- As part of the agreement, Bayer Taiwan Co. Ltd. will be responsible for securing Taiwanese more...
  
• TPTX Today 08:47am
  TorreyPines Therapeutics Update: Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia- Announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as more...